Cargando…
Short-term treatments for acute cardiac care: inotropes and inodilators
Acute heart failure (AHF) continues to be a substantial cause of illness and death, with in-hospital and 3-month mortality rates of 5% and 10%, respectively, and 6-month re-admission rates in excess of 50% in a range of clinical trials and registry studies; the European Society of Cardiology (ESC) H...
Autores principales: | Guarracino, Fabio, Zima, Endre, Pollesello, Piero, Masip, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225903/ https://www.ncbi.nlm.nih.gov/pubmed/32431568 http://dx.doi.org/10.1093/eurheartj/suaa090 |
Ejemplares similares
-
Differential effects of inotropes and inodilators on renal function in acute cardiac care
por: Zima, Endre, et al.
Publicado: (2020) -
Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014) -
The inodilator levosimendan as a treatment for acute heart failure in various settings
por: Gustafsson, Finn, et al.
Publicado: (2017) -
Epinephrine, inodilator, or no inotrope in venoarterial extracorporeal membrane oxygenation implantation: a single-center experience
por: Zotzmann, Viviane, et al.
Publicado: (2019) -
Epinephrine, inodilator, or no inotrope in venoarterial extracorporeal membrane oxygenation implantation: a single-center experience—an RCT would be desirable
por: Jouffroy, Romain, et al.
Publicado: (2020)